ORIGINAL RESEARCH article
Front. Immunol.
Sec. Molecular Innate Immunity
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1620229
This article is part of the Research TopicInnovative Insights into Pattern Recognition and Signaling in Innate ImmunityView all 7 articles
Differential Modulation of SARS-CoV-2 Infection by Complement Factor H and Properdin
Provisionally accepted- 1Biosciences, United Arab Emirates University, Al-Ain, United Arab Emirates
- 2Umea University, Umea, Sweden
- 3ICMR NIRRCH, Mumbai, India
- 4University of Kent and Greenwich, Kent, United Kingdom
- 5Brunel University of London, London, United Kingdom
- 6UAE University, Al Ain, United Arab Emirates
- 7University of Oxford, Oxford, United Kingdom
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
An unbalanced immune response and excessive inflammation are the major hallmarks of severe SARS-CoV-2 infection. The dysregulation of the complement system is known as a crucial factor in the immunopathology of SARS-CoV-2 infection. Complement alternative pathway has been linked to the excessive inflammation in severe SARS-CoV-2 infection in which decreased and elevated levels of factor H (FH) and properdin (FP), respectively were observed. The current study investigated the potential immunomodulatory roles of FP and FH against SARS-CoV-2 infection. The interactions between FH and FP and the SARS-CoV-2 spike (S) and its receptor binding domain (RBD) were evaluated using direct ELISA. The cell binding and luciferase based viral entry assays utilising S protein expressing lentiviral pseudotypes were used to assess the effects of FH, FP, and recombinant thrombospondin repeats 4 and 5 (TSR4+5) on SARS-CoV-2 cell entry. Using RT-qPCR, we also assessed the effects of FH and FP in the cytokine response induced by SARS-CoV-2 pseudotypes. FH and FP bound to RBD and SARS-CoV-2 S protein. The treatment with FP or TSR4+5 enhanced cell binding and entry of SARS-CoV-2 pseudotypes that was administered in A549 cells expressing human ACE2 and TMPRSS2 (A549-hACE2+TMPRSS2 cells). FP increases the affinity between host ACE2 and SARS-CoV-2, according to in silico analysis. In A549-hACE2+TMPRSS2 cells, the effect of FP on viral cell entry and binding was counteracted by anti-FP antibody treatment. SARS-CoV-2 lentiviral pseudotypes' cell entry and binding were decreased by FH. The A549-hACE2+TMPRSS2 cells that were challenged with SARS-CoV-2 alphaviral pseudotypes (expressing spike, envelope, nucleocapsid, and membrane proteins) pre-treated with FP or TSR4+5 showed an upregulation of pro-inflammatory cytokine transcripts, including NF-B and IL-1β, IL-8, IL-6, TNF-α, IFN-α, and RANTES. Contrary to this, the expression of these pro-inflammatory cytokines was downregulated by FH treatment. FH treatment decreased S protein-mediated NF-κB activation, but FP treatment enhanced it in A549-hACE2+TMPRSS2 cells. These results imply that FH may function as a SARS-CoV-2 cell entry and binding inhibitor, reducing the inflammatory response linked to infection independently of complement activation. FP could aid cell viral entry and binding and aggravate hyperinflammation that might contribute to the severity of the infection.
Keywords: Innate immune system, complement system, alternative pathway, Properdin, factor H, SARS-CoV-2, COVID-19, Cytokine response
Received: 29 Apr 2025; Accepted: 09 Jul 2025.
Copyright: © 2025 Kishore, Varghese, Kumar, Idicula-Thomas, Mayora Neto, Tsolaki, Ponnachan, Masmoudi, Al-Ramadi, Vatish, Madan, Temperton and Beirag. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Uday Kishore, Biosciences, United Arab Emirates University, Al-Ain, UB8 3PH, United Arab Emirates
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.